AcquisitionOther
Q32 Bio Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Q32 Bio Inc. -> target · $42 million
We are thrilled to be completing this transformative transaction that propels Q32 into its next stage of growth. Bempikibart, Q32 Bios most advanced product candidate, is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by
Open source record (SEC) ↗